David C Dvorak Invests $5 Million in THINK Surgical

David C Dvorak investment was completed through Black Lake Expeditions, LLC, an entity for which Mr. Dvorak serves as managing director. Mr. Dvorak became THINK Surgical’s Executive Chairman of the Board last year following an extensive search process.

David C Dvorak had a successful 16-year career at Zimmer Biomet Holdings, Inc. where he most recently held the position of president and chief executive officer for a decade.

“Since becoming THINK Surgical’s Chairman, I have gained a much deeper understanding of THINK’s overarching strategy and vision, current product offering and future technology pipeline, as well as the strength of its leadership team,” said Mr. Dvorak.  “Given his track record of success over decades with Stryker Corporation, including his time as president of the Joint Replacement Division and his experience with Mako robotic-arm technology, Stuart Simpson is uniquely qualified to lead THINK. I am highly confident that under Stuart’s leadership THINK will execute its compelling plans with precision and generate tremendous value for its stakeholders.”

“It is incredibly gratifying and motivating to receive such a significant demonstration of support from David,” said Stuart Simpson, president and chief executive officer of THINK Surgical.  “David’s decades of leadership experience in the orthopedic industry makes his investment a testament to the future growth potential of THINK Surgical.”

About THINK Surgical, Inc.
THINK Surgical, Inc., a privately held U.S.-based medical device and technology company, develops, manufactures, and markets active robotics for orthopedic surgery. The TSolution One® Total Knee Application includes the only commercially available, active robot for total knee arthroplasty (TKA) utilizing an open implant library, supporting a variety of implant options.  The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide.

THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent technology.  Please refer to the instructions for use for the TSolution One Total Knee Application for a complete list of indications, contraindications, warnings, and precautions.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version